company background image
3176 logo

Medigen Biotechnology TPEX:3176 Stock Report

Last Price

NT$39.10

Market Cap

NT$5.4b

7D

2.6%

1Y

20.7%

Updated

28 Mar, 2024

Data

Company Financials

Medigen Biotechnology Corp.

TPEX:3176 Stock Report

Market Cap: NT$5.4b

3176 Stock Overview

Medigen Biotechnology Corp., a biopharmaceutical company, focuses on the development of therapies for liver diseases and cancers in Taiwan.

3176 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Risk Analysis


Medigen Biotechnology Corp. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Medigen Biotechnology
Historical stock prices
Current Share PriceNT$39.10
52 Week HighNT$62.40
52 Week LowNT$30.30
Beta0.62
1 Month Change-7.67%
3 Month Change-12.72%
1 Year Change20.68%
3 Year Change-40.12%
5 Year Change-35.90%
Change since IPO104.71%

Recent News & Updates

Recent updates

Is Medigen Biotechnology (GTSM:3176) Using Debt Sensibly?

Apr 13
Is Medigen Biotechnology (GTSM:3176) Using Debt Sensibly?

Medigen Biotechnology (GTSM:3176) Shareholders Have Enjoyed A 83% Share Price Gain

Feb 19
Medigen Biotechnology (GTSM:3176) Shareholders Have Enjoyed A 83% Share Price Gain

Does Medigen Biotechnology (GTSM:3176) Have A Healthy Balance Sheet?

Dec 29
Does Medigen Biotechnology (GTSM:3176) Have A Healthy Balance Sheet?

Shareholder Returns

3176TW BiotechsTW Market
7D2.6%1.2%-0.3%
1Y20.7%-20.4%25.8%

Return vs Industry: 3176 exceeded the TW Biotechs industry which returned -21.1% over the past year.

Return vs Market: 3176 underperformed the TW Market which returned 26.7% over the past year.

Price Volatility

Is 3176's price volatile compared to industry and market?
3176 volatility
3176 Average Weekly Movement4.9%
Biotechs Industry Average Movement4.3%
Market Average Movement4.2%
10% most volatile stocks in TW Market8.1%
10% least volatile stocks in TW Market1.9%

Stable Share Price: 3176 has not had significant price volatility in the past 3 months.

Volatility Over Time: 3176's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1999n/aShun-Lang Changhttps://www.medigen.com.tw

Medigen Biotechnology Corp., a biopharmaceutical company, focuses on the development of therapies for liver diseases and cancers in Taiwan. It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells. It also develops OBP-301 that has completed Phase I clinical trials in combination with esophageal cancer in Japan; is in Phase I clinical trials in combination with immune checkpoint inhibitors (ICI) for patients with esophageal cancer in Japan; and in phase II study in combination with ICI for esophageal cancer and gastric cancer patients in the United States.

Medigen Biotechnology Corp. Fundamentals Summary

How do Medigen Biotechnology's earnings and revenue compare to its market cap?
3176 fundamental statistics
Market capNT$5.45b
Earnings (TTM)-NT$561.30m
Revenue (TTM)NT$1.16b

4.7x

P/S Ratio

-9.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
3176 income statement (TTM)
RevenueNT$1.16b
Cost of RevenueNT$540.39m
Gross ProfitNT$617.33m
Other ExpensesNT$1.18b
Earnings-NT$561.30m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-4.03
Gross Margin53.32%
Net Profit Margin-48.48%
Debt/Equity Ratio51.6%

How did 3176 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.